Acute and Longer-Term Safety Results from a Pooled Analysis of Duloxetine Studies for the Treatment of Children and Adolescents with Major Depressive Disorder
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess acute and longer-term safety of duloxetine in the treatment of children and adolescents with major depressive disorder (MDD), a pooled analysis of data from two completed randomized, double-blind, multicenter, phase 3, placebo- and active-controlled trials was undertaken. In these studies, neither duloxetine (investigational drug) nor fluoxetine (active control) demonstrated a statistically significant improvement compared with placebo on the primary efficacy measure. METHODS: Patients ages 7-17 years with MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) received duloxetine (n=341), fluoxetine (n=234), or placebo (n=225) for 10 week acute and 26 week extended (duloxetine or fluoxetine only) treatments. Safety measures included treatment-emergent adverse events (TEAEs), the Columbia-Suicide Severity Rating Scale, vital signs, electrocardiograms, laboratory samples, and growth (height and weight) assessments. RESULTS: Significantly more patients discontinued because of adverse events during duloxetine (8.2%) treatment than during placebo (3.1%) treatment (p≤0.05). TEAEs in >10% of duloxetine-treated patients were headache and nausea. No completed suicides or deaths occurred. During acute treatment, 6.6% of duloxetine-, 8.0% of fluoxetine-, and 8.2% of placebo-treated patients had worsening suicidal ideation from baseline. Among patients initially randomized to duloxetine or fluoxetine who had suicidal ideation at study baseline, 81% of duloxetine- and 77% of fluoxetine-treated patients had improvements in suicidal ideation at end-point in the 36-week studies. Suicidal behavior occurred in two fluoxetine-treated patients and one placebo-treated patient during acute treatment, and in seven duloxetine-treated patients and one fluoxetine-treated patient during extended treatment. Duloxetine-treated patients had a mean pulse increase of ∼3 beats per minute, and mean blood pressure (both systolic and diastolic) increases of <2.0 mm Hg at week 36. Weight decrease (≥3.5%) during acute treatment occurred with statistically (p≤0.05) greater frequency for both the duloxetine (11.4%) and fluoxetine (11.5%) groups versus the placebo (5.5%) group; however, mean weight increase occurred for both duloxetine and fluoxetine groups during extended treatment. CONCLUSION: Results from this pooled analysis of two studies were consistent with the known safety and tolerability profile of duloxetine. Clinical Trial Registry Numbers: NCT00849901 and NCT00849693.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056 · cited 1×
“M ajor depressive disorder (MDD) is a common illness in the pediatric population, with a prevalence of 2% in children and 4–8% in adolescents (Birmaher et al. 2007).”
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256 · cited 1×
“Among studies of antidepressants in the pediatric MDD population, SSRIs have been the most commonly studied class of antidepressants, with fewer studies of antidepressants with other mechanisms of action, such as mirtazapine or venlafaxine (Bridge et al. 2009).”
Cited by
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Zhong, Z., Wang, L., Wen, X., Liu, Y., Fan, Y., & Liu, Z. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s141832 · Cited by 46
“In addition, this greater increase in BP from baseline in SNRI-treated patients compared with SSRI-treated patients is consistent with the pharmacological actions, which are actions on both serotonergic and noradrenergic neurotransmission and on serotonergic neurotransmission.(30) A 3 mmHg difference in SBP may be tho…”
Upadhyaya, H. P., Arnold, L. M., Alaka, K., Qiao, M., Williams, D., & Mehta, R. (2019) · Pediatric Rheumatology · doi:10.1186/s12969-019-0325-6 · Cited by 45
Ignaszewski, M. J., & Waslick, B. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0174 · Cited by 37
“2013; Emslie et al. 2015).”
Metadata
- Authors
- Emslie, G. J., Wells, T. G., Prakash, A., Zhang, Q., Pangallo, B. A., Bangs, M. E., & March, J. S.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-05
- Volume
- 25
- Issue
- 4
- Pages
- 293-305
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1923228378
- Cited by
- 15
- References
- 3
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute and Longer-Term Safety Results from a Pooled Analysis of Duloxetine Studies for the Treatment of Children and Adolescents with Major Depressive Disorder. https://app.cochat.ai/papers/10.1089/cap.2014.0076
- The paper
- Emslie, G. J., Wells, T. G., Prakash, A., Zhang, Q., Pangallo, B. A., Bangs, M. E., & March, J. S. (2015). Acute and Longer-Term Safety Results from a Pooled Analysis of Duloxetine Studies for the Treatment of Children and Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2014.0076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.